Lidia Gil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lidia Gil has a total of 129 co-authors. Here are the top co-authors by number of shared publications:
- Dominik Dytfeld
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland
5 shared publications - Anna Łojko-Dankowska
Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznań, Poland
4 shared publications - Joanna Rupa-Matysek
Department of Hematology, Transplantation and Cellular Therapy, Poznan University of Medical Sciences, 84 Szamarzewskiego Street, 60-569 Poznan, Poland
4 shared publications - Katarzyna Brzezniakiewicz-Janus
Department of Hematology, Multi-specialist Hospital Gorzow Wlkp, University of Zielona Gora, Zielona Gora, Poland
4 shared publications - Jan Maciej Zaucha
Department of Haematology and Transplantology Medical University of Gdańsk Gdańsk Poland
3 shared publications - Agnieszka Piekarska
Medical University of Gdansk
2 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by Springer Nature in Annals of Hematology
Impact of invasive fungal disease on outcomes in adult allogeneic hematopoietic cell transplantation: a post-hoc analysis from a nationwide Polish Adult Leukemia Group study
The present analysis is based on a retrospective cross-sectional Polish study including patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) over a 3-year period (2012–2014). The aim of the study was to evaluate the impact of the updated 2019 invasive fungal disease (IFD) diagnostic criteria on treatment outcomes and to identify risk factors for mortality. The analysis included 102 patients diagnosed with IFD for whom follow-up data were available. In accordance with the 2019 EORTC/MSGERC consensus revisions, all IFD diagnoses were re-evaluated using the available clinical data. Additionally, due to the lack of therapeutic drug monitoring (TDM), patients receiving oral posaconazole suspension who presented with multiple risk factors for IFD and radiological findings on high-resolution chest computed tomography (HRCT) suggestive of fungal infection were classified as probable IFD cases, even in the presence of negative serum galactomannan (GM) results. Using the 2008 EORTC/MSG criteria, 3-month mortality rates were comparable between patients with probable and proven IFD (47.4% and 50%, respectively) and lower among patients classified as possible IFD (27.9%). In contrast, application of the modified 2019 IFD definitions resulted in a clearer stratification of patients into possible, probable, and proven IFD categories, with distinct 3-month mortality rates of 16%, 36%, and 52.4%, respectively. In multivariate analysis, neutropenia occurring at any time after transplantation – a major risk factor for IFD development – was independently associated with increased mortality. Moreover, proven IFD diagnosed according to the updated criteria significantly increased the risk of IFD-related death. In conclusion, reclassification of IFD according to updated criteria and adjustment for historical diagnostic limitations improved prognostic stratification, yielding clinically meaningful differences in mortality among possible, probable, and proven IFD cases.
- 16 November 2026
- Published by Springer Nature in Annals of Hematology
Open AccessImpact of invasive fungal disease on outcomes in adult allogeneic hematopoietic cell transplantation: a post-hoc analysis from a nationwide Polish Adult Leukemia Group study
The present analysis is based on a retrospective cross-sectional Polish study including patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) over a 3-year period (2012–2014). The aim of the study was to evaluate the impact of the updated 2019 invasive fungal disease (IFD) diagnostic criteria on treatment outcomes and to identify risk factors for mortality. The analysis included 102 patients diagnosed with IFD for whom follow-up data were available. In accordance with the 2019 EORTC/MSGERC consensus revisions, all IFD diagnoses were re-evaluated using the available clinical data. Additionally, due to the lack of therapeutic drug monitoring (TDM), patients receiving oral posaconazole suspension who presented with multiple risk factors for IFD and radiological findings on high-resolution chest computed tomography (HRCT) suggestive of fungal infection were classified as probable IFD cases, even in the presence of negative serum galactomannan (GM) results. Using the 2008 EORTC/MSG criteria, 3-month mortality rates were comparable between patients with probable and proven IFD (47.4% and 50%, respectively) and lower among patients classified as possible IFD (27.9%). In contrast, application of the modified 2019 IFD definitions resulted in a clearer stratification of patients into possible, probable, and proven IFD categories, with distinct 3-month mortality rates of 16%, 36%, and 52.4%, respectively. In multivariate analysis, neutropenia occurring at any time after transplantation – a major risk factor for IFD development – was independently associated with increased mortality. Moreover, proven IFD diagnosed according to the updated criteria significantly increased the risk of IFD-related death. In conclusion, reclassification of IFD according to updated criteria and adjustment for historical diagnostic limitations improved prognostic stratification, yielding clinically meaningful differences in mortality among possible, probable, and proven IFD cases.
- Open Access
- 15 October 2026
- Published by Springer Nature in Annals of Hematology
Evolving infectious epidemiology in acute myeloid leukemia in the contemporary era: a 13-year retrospective, single-center analysis of induction therapies
We evaluated the 13-year (2012–2025) evolution of infectious epidemiology in a Polish acute myeloid leukemia (AML) induction cohort, contextualizing these findings within shifting antimicrobial resistance (AMR), the SARS-CoV-2 pandemic, changing prophylaxis protocols (including fluoroquinolone cessation), and evolving diagnostic methodologies. Secondarily, we compared historical standard induction therapy (SIT) and novel targeted induction (NIT) regimens. This exploratory, retrospective, single-center study assessed induction-related infections in 219 newly diagnosed AML adults. We observationally evaluated temporal shifts in etiology and AMR, utilizing an interrupted time series approach to assess the 2018 cessation of universal fluoroquinolone prophylaxis, alongside a secondary comparison of SIT (n=189) and NIT (n=30) cohorts. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.Overall 30-day mortality was 8.2%. Comparing the pre-2018 (active fluoroquinolone) and post-2018 (discontinued) eras, proportional bloodstream infections (BSI; 40.6% vs. 34.7%) and multidrug-resistant organism (MDRO) rates (77.2% vs. 68.6%) decreased, without a compensatory Gram-negative surge. Concurrently, 30-day mortality dropped from 11.9% to 5.1%. Between NIT and SIT, incidences of microbiologically documented infections (53.3% vs. 51.3%), invasive fungal diseases (6.7% vs. 13.2%), and BSI (33.3% vs. 38.1%) were comparable. The higher incidence of VIM-producing Pseudomonas aeruginosa (30.8% vs. 3.3%; p=0.005) and SARS-CoV-2 (53.3% vs. 33.3%; p=0.034) in NIT was confounded by total overlap with the pandemic era and advanced molecular diagnostics. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.
- 15 October 2026
- Published by Springer Nature in Annals of Hematology
Open AccessEvolving infectious epidemiology in acute myeloid leukemia in the contemporary era: a 13-year retrospective, single-center analysis of induction therapies
We evaluated the 13-year (2012–2025) evolution of infectious epidemiology in a Polish acute myeloid leukemia (AML) induction cohort, contextualizing these findings within shifting antimicrobial resistance (AMR), the SARS-CoV-2 pandemic, changing prophylaxis protocols (including fluoroquinolone cessation), and evolving diagnostic methodologies. Secondarily, we compared historical standard induction therapy (SIT) and novel targeted induction (NIT) regimens. This exploratory, retrospective, single-center study assessed induction-related infections in 219 newly diagnosed AML adults. We observationally evaluated temporal shifts in etiology and AMR, utilizing an interrupted time series approach to assess the 2018 cessation of universal fluoroquinolone prophylaxis, alongside a secondary comparison of SIT (n=189) and NIT (n=30) cohorts. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.Overall 30-day mortality was 8.2%. Comparing the pre-2018 (active fluoroquinolone) and post-2018 (discontinued) eras, proportional bloodstream infections (BSI; 40.6% vs. 34.7%) and multidrug-resistant organism (MDRO) rates (77.2% vs. 68.6%) decreased, without a compensatory Gram-negative surge. Concurrently, 30-day mortality dropped from 11.9% to 5.1%. Between NIT and SIT, incidences of microbiologically documented infections (53.3% vs. 51.3%), invasive fungal diseases (6.7% vs. 13.2%), and BSI (33.3% vs. 38.1%) were comparable. The higher incidence of VIM-producing Pseudomonas aeruginosa (30.8% vs. 3.3%; p=0.005) and SARS-CoV-2 (53.3% vs. 33.3%; p=0.034) in NIT was confounded by total overlap with the pandemic era and advanced molecular diagnostics. The evolving infectious etiology in AML is driven by temporal, diagnostic, and ecological transitions rather than novel agents. Halting fluoroquinolone prophylaxis was clinically safe. Integrating contemporary therapies requires continuously adapting supportive frameworks to local epidemiology.
- Open Access
- 29 May 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (7)
Diving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution
Purpose: The aim of this review is to summarize transcriptomic studies using single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq to investigate leukemic stem cells (LSCs) population in acute myeloid leukemia (AML). Methods: Literature for inclusion was identified through a PubMed search. Twenty-seven studies were analyzed, covering various aspects of LSCs biology, including epigenetic, transcriptional, and translational gene regulation, metabolic reprogramming or cellular differentiation. Results: The reviewed studies highlight the complexity of LSCs, including their quiescent state, state-to-state cellular plasticity, and metabolic reprogramming from glycolysis to lipogenesis. Comparative analyses of matched diagnostic and post-treatment samples provide insights into the dynamic behavior of LSCs during therapy. The findings also identify potential therapeutic targets and strategies to selectively eradicate LSCs. Conclusion: Single-cell RNA sequencing technologies offer unprecedented resolution for studying LSCs in AML, revealing cellular heterogeneity and dynamic evolution within these critical populations. Despite these advances, standardized criteria for LSCs identification are still needed, and longitudinal studies at clinically relevant time points are essential to fully understand their role in disease progression and therapy resistance. Such approaches may ultimately uncover novel therapeutic vulnerabilities and improve clinical management of AML.
- 29 May 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (7)
Open AccessDiving into the transcriptional landscape of leukemic stem cells in acute myeloid leukemia at single-cell resolution
Purpose: The aim of this review is to summarize transcriptomic studies using single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq to investigate leukemic stem cells (LSCs) population in acute myeloid leukemia (AML). Methods: Literature for inclusion was identified through a PubMed search. Twenty-seven studies were analyzed, covering various aspects of LSCs biology, including epigenetic, transcriptional, and translational gene regulation, metabolic reprogramming or cellular differentiation. Results: The reviewed studies highlight the complexity of LSCs, including their quiescent state, state-to-state cellular plasticity, and metabolic reprogramming from glycolysis to lipogenesis. Comparative analyses of matched diagnostic and post-treatment samples provide insights into the dynamic behavior of LSCs during therapy. The findings also identify potential therapeutic targets and strategies to selectively eradicate LSCs. Conclusion: Single-cell RNA sequencing technologies offer unprecedented resolution for studying LSCs in AML, revealing cellular heterogeneity and dynamic evolution within these critical populations. Despite these advances, standardized criteria for LSCs identification are still needed, and longitudinal studies at clinically relevant time points are essential to fully understand their role in disease progression and therapy resistance. Such approaches may ultimately uncover novel therapeutic vulnerabilities and improve clinical management of AML.
- Open Access
- 12 February 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (1) , 551-554
Introducing CAR T-cell therapy into clinical practice for mantle cell lymphoma: real-world experience from Poland
- 12 February 2026
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22 (1) , 551-554
Open AccessIntroducing CAR T-cell therapy into clinical practice for mantle cell lymphoma: real-world experience from Poland
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 18, 1-7
Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer – A Case Report and Experience-Driven Strategy
Background: Breast cancer (BC) represents the most frequent female malignancy worldwide, and one of the rare, however life-threatening, complications after oncological treatment is acute myeloid leukemia post cytotoxic therapy (AML-pCT). Moreover, most AML-pCT cases have contributed to previous BC cytotoxic therapies. The treatment approach for AML-pCT in BC survivors with an active second BC represents the challenging decision-making process that is described in this report. Results: A 48-year-old woman was diagnosed with invasive lobular carcinoma of the right breast (T2N0M0, BRCA1 negative) and successfully treated with breast-conserving therapy, adjuvant radiotherapy, and hormone therapy. Seven years later, she was diagnosed with ductal carcinoma in situ in the left breast, and unexpectedly, directly before the surgery, with leukocytosis, anemia, and thrombocytopenia. Hematological investigation revealed a diagnosis of AML-pCT (intermediate ELN2022 risk group). After a management conference involving both oncologists and haematologists, conserving surgery of the left breast (pTis, pNX) was performed. Seven days later the patient started intensive antileukemic treatment with “ 3+7” induction chemotherapy, followed by two consolidation chemotherapies, which resulted in complete remission (CR) of leukemia with negative measurable residual disease. Despite a high hematopoietic cell transplantation comorbidity index score (due to a previous neoplasm), the patient qualified for allogeneic hematopoietic cell transplantation (alloHCT). The procedure was performed using myeloablative conditioning with a matched unrelated donor. Currently, 3 years post-alloHCT, the patient remains in CR for all three neoplasms. Conclusion: In this case report, we describe the therapeutic success of intensive alloHCT in AML-pCT patient with active BC. The presented treatment approach for active BC and AML-pCT requires collaboration between oncologists and hematologists to ensure fast decision-making.
- 1 January 2026
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 18, 1-7
Open AccessChallenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer – A Case Report and Experience-Driven Strategy
Background: Breast cancer (BC) represents the most frequent female malignancy worldwide, and one of the rare, however life-threatening, complications after oncological treatment is acute myeloid leukemia post cytotoxic therapy (AML-pCT). Moreover, most AML-pCT cases have contributed to previous BC cytotoxic therapies. The treatment approach for AML-pCT in BC survivors with an active second BC represents the challenging decision-making process that is described in this report. Results: A 48-year-old woman was diagnosed with invasive lobular carcinoma of the right breast (T2N0M0, BRCA1 negative) and successfully treated with breast-conserving therapy, adjuvant radiotherapy, and hormone therapy. Seven years later, she was diagnosed with ductal carcinoma in situ in the left breast, and unexpectedly, directly before the surgery, with leukocytosis, anemia, and thrombocytopenia. Hematological investigation revealed a diagnosis of AML-pCT (intermediate ELN2022 risk group). After a management conference involving both oncologists and haematologists, conserving surgery of the left breast (pTis, pNX) was performed. Seven days later the patient started intensive antileukemic treatment with “ 3+7” induction chemotherapy, followed by two consolidation chemotherapies, which resulted in complete remission (CR) of leukemia with negative measurable residual disease. Despite a high hematopoietic cell transplantation comorbidity index score (due to a previous neoplasm), the patient qualified for allogeneic hematopoietic cell transplantation (alloHCT). The procedure was performed using myeloablative conditioning with a matched unrelated donor. Currently, 3 years post-alloHCT, the patient remains in CR for all three neoplasms. Conclusion: In this case report, we describe the therapeutic success of intensive alloHCT in AML-pCT patient with active BC. The presented treatment approach for active BC and AML-pCT requires collaboration between oncologists and hematologists to ensure fast decision-making.
- 10 December 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Secondary cancers in breast cancer survivors. A two-centre study
Introduction: The risk of secondary cancers in breast cancer survivors remains a significant concern. This study aimed to evaluate the association between treatment modalities and the time to development of secondary cancers in patients after mastectomy or breast-conserving therapy (BCT). Material and methods: A retrospective analysis was conducted on 6590 patients from 2 centres (Poznan and Gorzow, Poland) treated for breast cancer between 2017 and 2022. A total of 149 patients from this group developed secondary cancer. Data included demographic and clinical characteristics, treatment types (chemotherapy, hormonotherapy, radiotherapy), and subtypes of primary breast cancer (luminal, triple negative, HER2 positive). Statistical methods included Kaplan-Meier analysis, Cox proportional hazards models, and X2 tests. Results: The median time to secondary cancer detection was significantly shorter in patients with TNBC/HER2+ subtypes (2.8 years) compared to luminal subtypes (6.1 years; p = 0.024). TNBC/HER2+ subtypes were associated with a 1.9-fold increased risk of secondary cancers (HR = 1.93; p = 0.048). No significant association was found between treatment type and the occurrence of secondary cancers (p > 0.05). However, combined therapies (e.g. chemotherapy + hormonotherapy) showed a trend toward reduced risk (HR = 0.53; p = 0.061). The most common secondary cancers were gastrointestinal malignancies (27%) and gynaecological cancers (15%). Conclusions: The subtype of primary breast cancer significantly influences the time to secondary cancer development, with TNBC/HER2+ patients at higher risk. Treatment modalities did not significantly affect secondary cancer risk, but combined therapies may offer protective effects. These findings highlight the need for tailored surveillance strategies based on tumour biology.
- 10 December 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Secondary cancers in breast cancer survivors. A two-centre study
Introduction: The risk of secondary cancers in breast cancer survivors remains a significant concern. This study aimed to evaluate the association between treatment modalities and the time to development of secondary cancers in patients after mastectomy or breast-conserving therapy (BCT). Material and methods: A retrospective analysis was conducted on 6590 patients from 2 centres (Poznan and Gorzow, Poland) treated for breast cancer between 2017 and 2022. A total of 149 patients from this group developed secondary cancer. Data included demographic and clinical characteristics, treatment types (chemotherapy, hormonotherapy, radiotherapy), and subtypes of primary breast cancer (luminal, triple negative, HER2 positive). Statistical methods included Kaplan-Meier analysis, Cox proportional hazards models, and X2 tests. Results: The median time to secondary cancer detection was significantly shorter in patients with TNBC/HER2+ subtypes (2.8 years) compared to luminal subtypes (6.1 years; p = 0.024). TNBC/HER2+ subtypes were associated with a 1.9-fold increased risk of secondary cancers (HR = 1.93; p = 0.048). No significant association was found between treatment type and the occurrence of secondary cancers (p > 0.05). However, combined therapies (e.g. chemotherapy + hormonotherapy) showed a trend toward reduced risk (HR = 0.53; p = 0.061). The most common secondary cancers were gastrointestinal malignancies (27%) and gynaecological cancers (15%). Conclusions: The subtype of primary breast cancer significantly influences the time to secondary cancer development, with TNBC/HER2+ patients at higher risk. Treatment modalities did not significantly affect secondary cancer risk, but combined therapies may offer protective effects. These findings highlight the need for tailored surveillance strategies based on tumour biology.
- Open Access
- 21 October 2024
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (9)
Microbial metabolomics in acute myeloid leukemia: From pathogenesis to treatment
Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.
- 21 October 2024
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 34 (9)
Open AccessMicrobial metabolomics in acute myeloid leukemia: From pathogenesis to treatment
Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.
- Open Access
- 29 August 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (2) , 855-865
Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease
Acute Graft versus Host Disease (aGvHD) is a common immunological complication occurring in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Moreover, aGvHD is associated with a higher risk of infections and metabolic complications, affecting non-relapse mortality. Progress in transplantation has changed the prophylactic and therapeutic strategies of aGvHD and improved patient outcomes. The standard first-line therapy remains steroids, with a response rate of about 50%. The Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, is an effective second-line therapy. The management of patients who developed a disease that is refractory to steroids and ruxolitinib, especially in the severe gastrointestinal forms of aGvHD, is not validated and remains an unmet medical need. In the article, we present the current clinical practice, as well as the latest advances targeting pathophysiological pathways of GvHD and gut microbiota, which may be a potential future of aGvHD therapy.
- 29 August 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (2) , 855-865
Open AccessRecent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease
Acute Graft versus Host Disease (aGvHD) is a common immunological complication occurring in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Moreover, aGvHD is associated with a higher risk of infections and metabolic complications, affecting non-relapse mortality. Progress in transplantation has changed the prophylactic and therapeutic strategies of aGvHD and improved patient outcomes. The standard first-line therapy remains steroids, with a response rate of about 50%. The Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, is an effective second-line therapy. The management of patients who developed a disease that is refractory to steroids and ruxolitinib, especially in the severe gastrointestinal forms of aGvHD, is not validated and remains an unmet medical need. In the article, we present the current clinical practice, as well as the latest advances targeting pathophysiological pathways of GvHD and gut microbiota, which may be a potential future of aGvHD therapy.
- Open Access
- 19 June 2024
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 93 (2) , e934
Maintenance therapy after Autologous Stem Cell Transplantation in Multiple Myeloma – currents and perspectives
MM is non-curable cancer that arises from plasma cells and is the second most common type of blood cancer. Drug-refractory relapses are inevitable, making it essential to sustain long-lasting remissions as part of therapy. Lenalidomide maintenance until progression is a standard of care for transplant-eligible newly-diagnosed patients. However, poor outcomes of high-risk patients and the risk of secondary primary malignancies associated with maintenance underline the need for novel approaches. Significant changes in frontline treatment maintenance are expected, with the increasing importance of minimal residual disease monitoring and the development of novel drug combinations for maintenance. This article explores current standards and prospects for maintaining response after upfront in ASCT in MM.
- 19 June 2024
- Published by Poznan University of Medical Sciences in Journal of Medical Science
- Vol. 93 (2) , e934
Open AccessMaintenance therapy after Autologous Stem Cell Transplantation in Multiple Myeloma – currents and perspectives
MM is non-curable cancer that arises from plasma cells and is the second most common type of blood cancer. Drug-refractory relapses are inevitable, making it essential to sustain long-lasting remissions as part of therapy. Lenalidomide maintenance until progression is a standard of care for transplant-eligible newly-diagnosed patients. However, poor outcomes of high-risk patients and the risk of secondary primary malignancies associated with maintenance underline the need for novel approaches. Significant changes in frontline treatment maintenance are expected, with the increasing importance of minimal residual disease monitoring and the development of novel drug combinations for maintenance. This article explores current standards and prospects for maintaining response after upfront in ASCT in MM.
- Open Access
- 11 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Effective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group
Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes. Retrospective and prospective data of patients with CDI after allo-HCT were assessed. We noted statistically significant increase in the incidence of acute GVHD and acute GI-GVHD after CDI (P = 0.005 and P = 0.016, respectively). The first-line treatment for CDI included metronidazole in 34 patients, vancomycin in 64, and combination therapy in 10. Treatment failure was more common with metronidazole than vancomycin (38.2% vs. 6.2%; P < 0.001). The need to administer second-line treatment was associated with the occurrence or exacerbation of GVHD (P < 0.05) and GI-GVHD (P < 0.001) and reduced overall survival (P < 0.05). In the multivariate analysis, the risk of death was associated with acute GVHD presence before CDI (hazard ratio [HR], 3.19; P = 0.009) and the need to switch to second-line treatment (HR, 4.83; P < 0.001). The efficacy of the initial CDI treatment affects survival and occurrence of immune-mediated GI-GVHD after allo-HCT. Therefore, agents with higher efficacy than metronidazole (vancomycin or fidaxomicin) should be administered as the first-line treatment.
- 11 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessEffective treatment of Clostridioides difficile infection improves survival and affects graft-versus-host disease: a multicenter study by the Polish Adult Leukemia Group
Clostridioides difficile infection (CDI) is the most common cause of infectious diarrhea after allogeneic hematopoietic cell transplantation (allo-HCT). The impact of CDI and its treatment on allo-HCT outcomes and graft-versus-host disease (GVHD), including gastrointestinal GVHD (GI-GVHD) is not well established. This multicenter study assessed real-life data on the first-line treatment of CDI and its impact on allo-HCT outcomes. Retrospective and prospective data of patients with CDI after allo-HCT were assessed. We noted statistically significant increase in the incidence of acute GVHD and acute GI-GVHD after CDI (P = 0.005 and P = 0.016, respectively). The first-line treatment for CDI included metronidazole in 34 patients, vancomycin in 64, and combination therapy in 10. Treatment failure was more common with metronidazole than vancomycin (38.2% vs. 6.2%; P < 0.001). The need to administer second-line treatment was associated with the occurrence or exacerbation of GVHD (P < 0.05) and GI-GVHD (P < 0.001) and reduced overall survival (P < 0.05). In the multivariate analysis, the risk of death was associated with acute GVHD presence before CDI (hazard ratio [HR], 3.19; P = 0.009) and the need to switch to second-line treatment (HR, 4.83; P < 0.001). The efficacy of the initial CDI treatment affects survival and occurrence of immune-mediated GI-GVHD after allo-HCT. Therefore, agents with higher efficacy than metronidazole (vancomycin or fidaxomicin) should be administered as the first-line treatment.